NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rao M, Lamont JL, Chan J, et al. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 73 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. (Future Research Needs Papers, No. 23.)

Cover of Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 73 [Internet].

Show details

References

1.
Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20:637–64. [PubMed: 18070711]
2.
Ries LAG, Harkins D, Krapcho M, et al. SEER cancer statistics review, 1975–2003. Bethesda, MD: NCI; 2005. [Accessed January 30, 2012]. Available at: http://seer​.cancer.gov/csr/1975_2003.
3.
Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66. [PubMed: 17237035] [Cross Ref]
4.
Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57(5):301–8. [PubMed: 17855486] [Cross Ref]
5.
Cook R. An economic perspective on treatment options in multiple myeloma. Managed Care Oncol. 2007 Spring;:10–2.
6.
Messori A, Trippoli S, Santarlasci B. Pharmacotherapy of multiple myeloma: an economic perspective. Expert Opin Pharmacother. 2003 Apr 1;4(4):515–24. [PubMed: 12667114] [Cross Ref]
7.
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9. [PMC free article: PMC2627786] [PubMed: 18971951]
8.
Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Jun 4;23(10):1716–30. [PubMed: 19494840]
9.
Rajkumar SV. Clinical features, laboratory manifestations, and diagnosis of multiple myeloma. In: Basow DS, editor. Waltham, MA: 2011. UpToDate.
10.
Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001 Apr;47(4):673–80. [PubMed: 11274017]
11.
Rajkumar SV. Recognition of monoclonal proteins. In: Kyle RA, Connor RF, editors. Waltham, MA: 2011. UpToDate.
12.
Katzmann JA. Serum free light chains: quantitation and clinical utility in assessing monoclonal gammopathies. Clin Lab News. 2006 Jun:12–4.
13.
Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215–24. [PubMed: 19020545]
14.
Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004 Aug;126(3):348–54. [PubMed: 15257706]
15.
Sanchorawala V, Seldin DC, Magnani B, et al. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005 Oct;36(7):597–600. [PubMed: 16044137]
16.
Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun;24(6):1121–7. [PubMed: 20410922]
17.
Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem. 2005 May;51(5):805–7. [PubMed: 15855664]
18.
Whitlock EP, Lopez SA, Chang S, et al. AHRQ Series Paper 3: Identifying, selecting, and refining topics for comparative effectiveness systematic reviews: AHRQ and the Effective Health-Care program. J Clin Epidemiol. 2010;63:491–501. [PubMed: 19540721]
19.
Concannon T, Meissner P, Grunbaum J, et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J Gen Intern Med. 2012:1–7. [PMC free article: PMC3403141] [PubMed: 22528615]
20.
Trikalinos TA, Dahabreh IJ, Wong J, et al. Future Research Needs for the Comparison of Percutaneous Coronary Interventions with Bypass Graft Surgery in Nonacute Coronary Artery Disease: Identification of Future Research Needs from Comparative Effectiveness Review No. 9. Rockville, MD: Agency for Healthcare Research and Quality; Sep, 2010. [Accessed January 30, 2012]. [Internet] Available at: www​.effectivehealthcare.ahrq.gov. [PubMed: 21433325]
21.
Elliott BM, Peti S, Osman K, et al. Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol. 2011 Apr;86(4):289–98. [PubMed: 21198866]
22.
Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008 May 15;111(10):4908–15. [PMC free article: PMC2964259] [PubMed: 18364469]
23.
Giarin MM, Giaccone L, Sorasio R, et al. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem. 2009 Aug;55(8):1510–6. [PubMed: 19520760]
24.
Khoriaty R, Hussein MA, Faiman B, et al. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):E10–3. [PubMed: 20223721]
25.
Kroger N, Asenova S, Gerritzen A, et al. Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients. Blood. 2010 Apr 22;115(16):3413–4. [PubMed: 20413663]
26.
Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011 Mar;86(3):251–5. [PMC free article: PMC3773466] [PubMed: 21328431]
27.
Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 2007 May;137(3):240–3. [PubMed: 17408464]
28.
Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003 Jul;122(1):78–84. [PubMed: 12823348]
29.
van RF, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007 Aug 1;110(3):827–32. [PMC free article: PMC1924775] [PubMed: 17416735]
30.
Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011 Apr 20;29(12):1627–33. [PubMed: 21402611]
31.
Dytfeld D, Griffith KA, Friedman J, et al. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Leuk Lymphoma. 2011 Jul;52(7):1271–80. [PubMed: 21699382]
32.
Cohen AD, Zhou P, Chou J, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/− thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007 Oct;139(2):224–33. [PubMed: 17897298]
33.
Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol JASN. 2009 Apr;4(4):745–54. [PMC free article: PMC2666427] [PubMed: 19339414]
34.
Chee CE, Kumar S, Larson DR, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009 Sep 24;114(13):2617–8. [PMC free article: PMC2756122] [PubMed: 19641191]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (455K)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...